Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07137832 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion

Study acronym: PEARL-MeVO
StatusRecruiting
PhasePhase 3
Started2025-10-09
View on ClinicalTrials.gov ↗

Amendment history

2026-08-20
Study Identification, Study Status, Study Description, Arms and Interventions v3
InterventionsIntra-arterial thrombolysis as adjunct to endovascular treatment (Combination Product), Standard medical treatment (Other)→Primary intra-arterial thrombolysis (Combination Product), Standard medical treatment (Other)
Study description-16 characters
[...] nical trial aiming at evaluating the efficacy and safety of primary intra-arterial thrombolysis as adjunct to endovascular treatment in improving 90-day functional outcome in acute ischemic st [...] ed at a ratio of 1:1 into the intervention group to receive primary intra-arterial thrombolysis asin adjunctaddition to endovascularstandard medical treatment, or the control group to receive only standard me [...]
Study title-29 characters
OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis as Adjunct to Endovascular Treatment for Medium Vessel Occlusion
2026-04-14
Study Status, Contacts/Locations v2
Study sitescontacts updated at 1 of 1 site
2025-12-07
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-09-01→confirmed 2025-10-09
Study sitesdetails revised at 1 of 1 site
2025-08-15
Original filing
PEARL-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of primary intra-arterial thrombolysis in improving 90-day functional outcome in acute ischemic stroke patients due to medium vessel occlusion (MeVO) within 24 hours of symptom onset.
Trial Details
NCT Number NCT07137832
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Acute Ischemic Stroke
Enrollment 530 participants
Start Date 2025-10-09
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-24